Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20070803/NYF045LOGO )
As previously announced, Merck will fund development and commercializationof products that employ MicroDose's DPI technology for the administration ofMerck compounds. In addition to the upfront payment received uponcommencement of the collaboration, MicroDose is eligible for additionalmilestone payments on this product and for the development of other productsand royalties on revenues from all products developed under the license.
Advertisement
"MicroDose is proud to announce the start of the study by Merck which, infact, represents the second human clinical study to be initiated under a U.S.Investigational New Drug application using our inhaler technology in the last18 months" commented David Byron, Vice President of Research and Development,MicroDose. "Achieving this milestone with Merck so quickly is a strongindicator of the excellent working relationship that underpins thiscollaboration."
About the MicroDose DPI
The MicroDose DPI is among a number of key proprietary drug deliveryplatforms developed by MicroDose. By employing piezo electronics, theMicroDose DPI has the potential to deliver enhanced performance for efficientand reproducible delivery independent of patient coordination, inhalation rateand posture, features MicroDose hopes will be confirmed through clinicaltrials. MicroDose believes that the flexibility of the inhaler makes it atrue platform technology, able to support a broad pipeline of products acrossthe spectrum of patient populations and therapeutic categories.
About MicroDose Technologies
MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is aleading privately-held drug delivery systems company, developing advancedpulmonary, fixed-dose-combination oral dosage, and other technologies for thepharmaceutical and biotechnology industries.
In addition to the collaboration with Merck, MicroDose's otherpartnerships include; a multi-product development and licensing agreement withNovartis, the development of an inhaled insulin product through MicroDose'sQDose joint venture, and an inhaler for the systemic delivery of a nerve agentantidote for the U.S. Department of Defense, in collaboration with theUniversity of Pittsburgh. MicroDose has ongoing feasibility programs withother major pharmaceutical companies and is also conducting internaldevelopment programs for products employing its inhaler technology, and forcombination oral dosage products employing its PolyCap(TM) technology, in the
areas of diabetes, hypertension and hyperlipidemia. For more informationvisit us at http://www.microdose-tech.com
SOURCE MicroDose Technologies, Inc.